VantAI and TARA Biosystems Partner to Discover New Medicines

NEW YORK, NY - (EurekAlert) - VantAI and TARA Biosystems today announced the launch of a biology-driven, AI-enabled collaboration for accelerated cardiac drug development. The partnership will leverage TARA’s state-of-the-art in vitro human …

READ MORE

TARA Biosystems Announces $10 Million Series A2 Financing to Expand its Cardiac Disease Drug Discovery and Development Capabilities

NEW YORK, NY - (BUSINESS WIRE) - TARA Biosystems, Inc., a company generating in vitro human biology to increase the success of cardiac disease drug discovery and development, today announced a $10 million Series A2 …

READ MORE

Heart-on-a-Chip Technology Predicts Preclinical Systolic and Diastolic in vivo Observations for Novel Cardiac Drug in Development

NEW YORK, NY - (Newswire.com) - TARA Biosystems, Inc. today reported in vivo and in vitro functional data from a

READ MORE

TARA Biosystems Launches Cardiotype.Ca™ Cardiac Calcium Signaling Assay: In Vitro Assay Accelerates Drug Development in Human-Relevant Heart Models

​​ TARA Biosystems, Inc. launched Cardiotype.Ca™, its in vitro system for assessing cardiac calcium signaling. The new assay can be used independently or in combination with TARA’s <…

READ MORE

Heart-on-a-Chip Mimics Drug Response Seen in Humans: In Vitro Approach Provides Predictive Platform for Human-Based Drug Discovery

NEW YORK, N.Y. (Newswire.com)— Researchers from TARA Biosystems, Inc. and GlaxoSmithKline (GSK) today published data demonstrating that TARA’s engineered heart-on-a-chip system replicated drug responses found in adult humans. The

READ MORE

TARA Secures Exclusive Worldwide License to Columbia University Intellectual Property relating to Engineered Human Cardiac Tissues

NEW YORK, N.Y. (Newswire.com)— TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced the execution of an exclusive worldwide license agreement with Columbia …

READ MORE

TARA Announces Issuance of US Patent for Biowire™ II Platform

New York, NY, (Newswire.com) - TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced that the United States Patent and Trademark Office (USPTO) has …

READ MORE

TARA Biosystems Biowire™ II Heart-on-a-Chip Platform Published in CELL

NEW YORK, (Newswire.com) TARA Biosystems, Inc., a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced the first peer-reviewed publication of its Biowire™ II platform by a team of …

READ MORE

TARA Biosystems and Insilico Medicine Announce Drug Discovery Collaboration for Cardiac Disease

New York – TARA Biosystems, Inc. a company offering “heart-on-a-chip” tissue models for drug discovery and risk assessment applications and Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines for age-related diseases, announced today the launch of a collaboration to discover and develop novel therapies for …

READ MORE

TARA Launches Cardiotype.Fo, Best-In-Class Assay for Cardiac Contractility

New York, (Newswire.com) - TARA Biosystems, Inc. a company offering “heart-on-a-chip” tissue models for drug discovery and development applications announced today the launch of Cardiotype.Fo, the best-in-class in vitro system for assessment of cardiac …

READ MORE